2022 10 27 Transcription Résultats 9M-2022 (Version Anglaise uniquement)
Please note that the conference call was accompanied by a complementary presentation in PDF format available on the Group's website:http://www.coface.com/Investors, under the "Financial results and reports" section.
9M-2022 Results
Conference Call Transcription
IMPORTANT INFORMATION- In the conference call meeting upon which this transcript is based, Coface made certain forward-looking statements. Such forward looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. Forward-looking information and statements are not guarantees of future performance and are subject to various risks and uncertainties. Actual results could differ materially from those expressed in, or impliedor projected by,forward-lookinginformation and statements.
Readers should read the Interim financial report for the for the first half 2022 and complete this information with the Universal Registration Document for the year 2021, which was registered by the Autorité des marchés financiers ("AMF") on
Please refer to chapter 5 "Main risk factors and their management within the Group" of the
The information contained in the transcript is a textual representation of the conference call and while efforts are made to provide an accurate transcription, there may be material errors, omissions, or inaccuracies in the reporting of the substance of the conference calls. In no way does Coface assume any responsibility for anyinvestment or other decisions made based upon the information provided on this transcript.
Presentation
Moderator
Ladies and gentlemen, welcome to the conference call for the presentation of Coface's results for the period ending
Xavier DURAND, CEO, COFACE
Thank you, and welcome everyone to this earnings call.
We're happy today to report our results for the first nine months of 2022. As you will see from the publication, it's been another record quarter for Coface. This is a bit of a paradox at the same time given the risks out there in the economy.
Just going quickly through the key numbers, you see that for the first nine months we're reporting €228m in profit, which is more than all of 2021. €84m of this was generated in the third quarter, which is actually our best quarter ever. Turnover is up 15.2% at constant FX and perimeter and almost 18% on a reported basis. TCI continues to grow nicely at 16.6%. We still see some of the same trends in play that we've already discussed in the prior quarters. I'm not going to repeat these. Client retention is at a record high. Pricing is continuously down at -3% in line with the first half of the year. Business information continues to see nice revenue growth, almost 16% at constant FX. The loss ratio is up but still very good at a 36.9% net ratio. The net combined ratio is up close to 8% at 63.8%. Gross loss ratio at 30% is up 5%. We're seeing continuous normalisation of the environment and I'll speak more to this in the later pages. The cost ratio is still very strong at slightly below 27% and we'll talk about what's involved in this. For Q3 the net combined ratio is just below 60%. The retuon average tangible equity stands at 16.4%, and tangible equity per share is at €11.50.
There were a couple of notable events in the quarter. We managed to successfully refinance our Tier 2 debt which was due in 2024, so we've actually de-risked that 2024 deadline, and we replaced the old debt with Solvency 2 compatible debt which is going to help our solvency ratio. Second, Moody's has reaffirmed our rating but this time with a positive outlook, which is notable in the face of the upcoming slowdown and great recognition of where we stand as a company, the consistency of our underwriting procedures and the contribution of the information business to a more stable business model.
The next page really talks about
Then I go to page 7 which starts the usual pages on growth. I've already mentioned the overall growth numbers. As I said, TCI continues to hold up nicely and is being driven by client activity and very strong retention. You're seeing some FX impact of the strong US dollar versus the euro in particular. Other revenues are up almost 10% and the information business grew close to 16% in the third quarter. We're still seeing lower debt collection fees, which at some point will tuaround. Factoring has been pretty good at
|
9M-2022 Results - conference call transcription - |
1 |
13% growth. And then another interesting feature is the nice reversal of growth for fees which has been decreasing now for a couple of years, and it is now up 6.7% at constant FX.
On page 8, you see the split by region and there's really not that much news here. WesteEurope, Med &
What you see on page 9 is a continuation of the story from the last couple of quarters. On one hand, our new business is the lowest that it's been in the last four years. I think we've been consistent with our philosophy, which is to create value through the cycle. So, we've been prudent and thoughtful in terms of underwriting new business in the face of a somewhat exuberant marketplace. We've been very focused on retaining our clients and our 93.5% retention rate is yet another record for the business. That's obviously coming at a price. The price effect is at -3.0%, which means we've given up the gains that we made during Covid in 2020 and 2021. Volume continues to be strong. The rebound from Covid plus inflation are driving 11% volume activity, which obviously benefits our activity as well.
When I go to the loss page on page 10, it's been another great quarter at 29.5% in Q3. We continue to see normalisation happening. The number of claims has been increasing since the middle of 2021 when we reached the trough, so we're nearing pre-crisis levels in terms of the number of claims. However, we're not seeing the large claims that we would normally see, so the large losses are still below the average. We've taken deliberate action to increase the reserves related to
On page 11 we go into the regional view, and you can see that the four largest and traditionally more stable markets at the bottom have been fairly stable with relatively benign losses. WesteEurope is at 23%, NortheEurope at 30%, Med &
If you go to page 12, you see the same story spelled out by quarter. What you see at the bottom is quite stable and good levels of losses in WesteEurope. In NortheEurope you see a peak and in
On the next page we talk about costs. Overall costs are growing quarter-on-quarter at a similar pace to our premiums, at 16% and there are two components to that. The first one has to do with the external acquisition costs, and you can see they're up 25 points. This is because there are some profit-sharing clauses in our contracts with clients, which when the losses are low means we pay more commissions and that's really playing out. So, part of this of this line is driven by the low losses that we're experiencing in the
|
9M-2022 Results - conference call transcription - |
2 |
book. Secondly, in dark blue here are the internal costs which are up 13.4%, and again within that you have a few different things at play. One is the investments that we're making in the business information line. The second one is that given the performance of the business, we anticipate that we're going to have higher costs in terms of incentives and profit shares with employees, so when you take that stuff out, you're down to 9.8% internal cost growth, and that's how I think we're continuing to drive positive operating leverage because our internal core costs are growing less than our premiums. So that has driven the net cost ratio for the first nine months of the year. The gross cost ratio is at 32.2% versus the 33.8% that we had in 2019 and 33% in 2021. Just to note again that given that the claims environment continues to be relatively low, debt collection revenues are also low.
That's the story for the costs, and I'm going to pass it on to Phalla to take us through the next pages as we usually do.
Phalla GERVAIS, Group CFO and Risk Director
Let's go to the reinsurance page, "record low past losses and commissions drive reinsurance result". If you look at the premium cession rate, it is at 27.1%, which is similar to the pre-Covid cession rate, prior to the backed-up period. This is back to a much more normal level. Then, if you look at the cession rate at 11%, I think there are two highlights here. First, if you remember in Q1 we put behind us the impact of the back stop when we released reserves that went back to the government that put in place the public schemes. And then, if you look at Q2 and Q3, the claim cession rate is pretty low as well, which is really linked to the low claims environment. Consequently, the insurance result ended up at €128m and that makes our reinsurers pretty happy.
On the next page, the net combined ratio has increased from 56.1% to 63.8%. Two components here - the net cost ratio is down almost four points. Of course, cost discipline is our DNA, but this is also due to higher commissions from reinsurance thanks to the renewal terms and conditions that we got at the end of 2021. The net loss ratio is up from 25.4% to 36.9%. This is driven by the fact that losses are normalising a little bit and of course all the additional results that were booked to
If we move to the next page, which is a view of our financial portfolio, the mark-to-market value is about €2.8bn. There are a couple of things to be noted here. First, you can see that we continue to de-risk our investment portfolio, reducing our equity exposure down to 3% in favour of bonds. The second thing is that we are still maintaining a very high level of liquidity. We're at 18% and this is really coming from the very strong cash generation resulting from the very strong business performance. This is helping us to reinvest at a much higher yield than we used to do in the past. Then, our hedging position is still in place, which also had a P&L impact this quarter. Net investment income has risen from almost €31m last year to €39m this year, with an accounting yield without realised gains up from 0.9% to 1.0%. I just want to highlight the fact that all the new money that we are reinvesting now is above 2%, so over time we're of course seeing investment income going up.
If we move to the next page, I also want to highlight that the €2.8bn doesn't take into account the additional cash that we have received from liability management. This cash totals almost €150m and is sitting in the current account as we speak, and it will be redeployed of course and reinvested at a much higher yield than we see today. We successfully managed our liabilities in September, de-risking the refinancing deadline that we have in 2024. There was a €380m Tier 2 loan that we have maturing in
|
9M-2022 Results - conference call transcription - |
3 |
there is a temporary impact on additional Tier 2 debt, with an additional 10 basis point impact on the Solvency 2 ratio until
If we move to the next page, we've generated stellar profits in the first nine months of the year. €228m of which €84m was generated in Q3, with operating income up 24% and net income up 20%.
If we move to the next page, the retuon average tangible equity stands at 16.4%. If we look at the change in equity, it stood at €2.1bn at the end of
Retuon average tangible equity has increased from 12.2% to 16.4% due to the technical and financial result net of tax. With this, I'll hand back over to Xavier.
Xavier DURAND
So just to wrap this up, it's been the best quarter in our history in many ways, including double digit revenue growth in TCI and in the business information space at 16.4%, as well as a low loss ratio despite the fact that we've actually increased our reserves on
So, with that I'm going to leave it to everyone for questions.
|
9M-2022 Results - conference call transcription - |
4 |
Pour lire la suite de ce noodl, vous pouvez consulter la version originale ici.
Attachments
Disclaimer



2022 10 27 Transcript Conference Call 9M-2022 Results (English version only)
Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean
Advisor News
- Proposed legislation takes aim at Social Security shortfall
- The overlooked retirement security risk that must be addressed
- What advisors should know about hedge funds in retirement planning
- Retirement control is top success measure for middle class, ACLI says
- Industry groups applaud House passage of Financial Exploitation Prevention Act
More Advisor NewsAnnuity News
- Built-in guaranteed annuities: What advisors should know
- Malibu Life Holdings Completes Acquisition of TruSpire, Establishing Malibu USA and Accelerating Entry into the U.S. Retail Annuity Market
- Why job boards are failing insurance agencies
- MassMutual Ranks No. 100 on the 2026 Fortune 500® List
- What’s fueling record annuity growth?
More Annuity NewsHealth/Employee Benefits News
- Rising health care costs are straining Texas businesses
- USPS CLEVELAND IS HIRING OVER 60 POSITIONS AVAILABLE
- How brokers can become ‘AI whisperers’
- Best's Review Leaders Issue Ranks Top Global Brokers and More
- Rising health care costs are straining Texas businesses as the Legislature seeks solutions
More Health/Employee Benefits NewsLife Insurance News
- Best's Review Leaders Issue Ranks Top Global Brokers and More
- Fortitude Re Announces $3.8 Billion Long-Term Care Reinsurance Agreement with Unum Group
- Unum Group Announces $3.8 Billion Long-Term Care Reinsurance Transaction with Fortitude Re
- Before you debate premium financing, understand the bigger picture
- NAIFA praises House committee approval of Clarity for Compensation Act
More Life Insurance News